PRESS



Press Releases

  Blue Therapeutics advances BLUE-181, a novel non-narcotic painkiller, as lead clinical candidate
June 18, 2018 | Cambridge, MA | PDF
  Blue Therapeutics has hired Lynn Webster, MD, as consulting partner to advise Blue on clinical trial design, Phase I analgesic efficacy readouts, human abuse liability assessment and clinical regulatory strategy. Dr. Webster is a past president of the American Academy of Pain Medicine and has board certifications in pain medicine, anesthesiology and addiction medicine, and has extensive experience supervising analgesic clinical trials.
May 2, 2018 | Cambridge, MA
  Blue Therapeutics CSO, Dr. Ajay Yekkirala to give webinar on June 21st entitled, "The Opioid Crisis and the Quest for Superior Analgesics without addiction". The webinar is sponsored by the American Chemical Society and registration is free and open to the public.
May 1, 2018 | Washington, DC
  Dr. Ajay Yekkirala, CSO of Blue Therapeutics, spoke today about the ongoing progress of Blue Therapeutics alongside Dr. Clifford Woolf of Harvard Medical School. This talk was part of the Harvard Medical School Longwood Seminar Series, entitled, "The Science of Pain Management". The entire talk is linked here.
March 28, 2018 | Boston, MA
  Blue Therapeutics CEO, Dr. Michio Painter, will speak today at the MassBio Annual Meeting as an invited panelist. He will participate on the panel, "Getting to Better Pain Relief" with other experts in the field, moderated by Dr. Peter Hein of Gruenenthal.
March 21, 2018 | Cambridge, MA
  Blue Therapeutics announces new headquarters located at 625 Mass Ave, Cambridge, MA 02139
March 1, 2018 | Cambridge, MA
  National Institute on Drug Abuse grants SBIR Phase I research grant to Blue Therapeutics to identify additional non-addictive analgesic molecules
January 18, 2018 | Washington, DC
  Dr. Ajay Yekkirala, CSO of Blue Therapeutics, co-authors review article in Anesthesia and Analgesia, titled "Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics"
November 5, 2017 | Baltimore, MD | PDF
  Janice Lansita, PhD, DABT, becomes consulting partner at Blue Therapeutics, where she will advise on pharmaceutical and toxicological regulatory planning and strategy
August 22, 2017 | Cambridge, MA
  Jim Dolan, MBA, joins Blue Therapeutics as a consulting partner, where he will evaluate partnership, licensing and acquisition opportunities and advise on strategy and structure of potential pharma partnerships or acquisition opportunities. Jim has a combined 35 years of pharma business development experience with emphasis in acquisitions, asset purchases, product licenses and discovery alliances in the analgesic space.
August 9, 2017 | Cambridge, MA
  Blue Therapeutics brings in Jim Joly, PhD, as consulting partner to provide technical guidance on preclinical safety and toxicology efforts
July 6, 2017 | Cambridge, MA
  Department of Defense awards $500,000 orthopedic research grant to Blue Therapeutics for "Development of a Novel, Nonaddictive Analgesic for Postsurgical Pain"
June 12, 2017 | Arlington, VA
  Dr. Ajay Yekkirala, CSO, and Dr. David Roberson, COO of Blue Therapeutics, together with Drs. Bruce Bean and Clifford Woolf of Harvard Medical School, publish article in Nature Reviews Drug Discovery, titled "Breaking barriers to novel analgesic drug development"
June 9, 2017 | New York, NY | PDF
  Blue Therapeutics forms consulting partnership with Organix, Inc. to assist with molecule design and synthesis of new chemical entities. The Organix team will be led by Peter Meltzer, PhD, CEO, and Anu Mahadevan, PhD, Vice President, who together bring over 50 years of synthetic organic chemistry and medicinal chemistry leadership expertise to Blue.
April 27, 2017 | Cambridge, MA
  Blue Therapeutics receives $15,000 Catalyst grant from the Roddenberry Foundation. This award will support novel intellectual property development and associated patent filings.
December 6, 2016 | Los Angeles, CA
  Blue Therapeutics awarded $1.4 million SBIR Phase II award from NIDA/NIH to fund IND-enabling studies of BLUE-181
July 25, 2016 | Washington, DC
  Robert Perni, PhD, Principal of JMD Pharma Creativity, brought on as consulting partner at Blue Therapeutics. Bob will be advising Blue on chemistry outsourcing, small molecule drug design strategy, and evaluation of new chemical entities.
August 27, 2015 | Cambridge, MA
  Blue Therapeutics Incorporates as Delaware C-corporation
May 5, 2015 | Cambridge, MA

Media Coverage

  CBS Philly runs piece highlighting the work of Ajay Yekkirala in developing BLUE-181: "Researchers Develop Non-Narcotic Pain Medicine"
June 10, 2018 | Philadelphia, PA | HD Video (2:25)
  CBS HealthWatch covers our work developing BLUE-181: "Researchers On Brink Of Non-Addictive Painkiller"
June 9, 2018 | Minneapolis, MN | HD Video (2:35)
  WBZ Evening News (Boston) carries news story on the potential of BLUE-181 to address the national opioid crisis: "Mass. Researchers May Be On Brink Of Creating Revolutionary, Non-Addictive Painkiller"
June 8, 2018 | Boston, MA | HD Video (1:52)
  Blue Therapeutics' work on the development of BLUE-181 is featured on CBS This Morning: "Researchers say they're on the verge of creating a revolutionary, non-addictive painkiller"
June 8, 2018 | New York, NY | HD Video (3:54)
  Article in The Scientist magazine, "The Quest for Safer Opioid Drugs", describes Dr. Yekkirala's efforts leading development of Blue181
January 1, 2018 | New York, NY
  Blue Therapeutics CSO, Dr. Ajay Yekkirala, interviewed for story in Chemical & Engineering News
November 13, 2017 | Boston, MA | PDF
  Blue Therapeutics featured in National Pain Report
January 6, 2016 | Boston, MA
  Blue Therapeutics featured in BostInno article
January 4, 2016 | Boston, MA
  Blue Therapeutics chosen as finalist in MassChallenge startup competition
May 20, 2015 | Cambridge, MA
  Blue Therapeutics chosen as runner-up in Harvard University's "Dean's Health and Life Science Challenge" business competition
April 30, 2015 | Cambridge, MA
  Blue Therapeutics chosen as finalist in OBR/SR-One OneStart startup competition
April 25, 2015 | San Fransisco, CA

Helpful Links